Collectively, their findings demonstrated that enhanced CYP ω-hydroxylases (generating HETEs) and sEH (degradating EETs) metabolic functions are associated with more advanced endothelial dysfunction and vascular inflammation, respectively, in patients with established atherosclerotic CVD. This evidence concerns the gene EPHX2 and endothelial dysfunction.